NEW YORK (GenomeWeb News) — Stem cell technology company VistaGen Therapeutics and the Wisconsin Alumni Research Foundation have signed an agreement for patents to technology developed at the University of Wisconsin – Madison that may be used as predictive drug screening assays.
 
South San Francisco-based VistaGen plans to use the technology to speed up development of customized, next-generation stem cell-based predictive toxicology and drug screening assays.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.